Streetbeat News

Analyst Ratings

ANET

Evercore ISI Group has maintained its 'Outperform' rating on Arista Networks and raised the price target from $400 to $425, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 5:10 pm

MRUS

Guggenheim analyst Michael Schmitz has maintained a Buy rating on Merus (NASDAQ:MRUS) and increased the price target from $93 to $111.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 5:10 pm

IGMS

Guggenheim has maintained its Buy rating on IGM Biosciences but has lowered the price target from $25 to $20.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 5:07 pm

ZBH

Evercore ISI Group has maintained an 'In-Line' rating on Zimmer Biomet Holdings (NYSE:ZBH) while lowering the price target from $113 to $110.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 5:07 pm

WAT

Evercore ISI Group has maintained an 'In-Line' rating for Waters Corporation (NYSE:WAT) and raised its price target from $335 to $355.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 5:06 pm

TWST

Evercore ISI Group has maintained an 'Outperform' rating on Twist Bioscience and raised its price target from $52 to $56.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 5:03 pm

CYBR

Wedbush analyst Daniel Ives maintains an Outperform rating on CyberArk Software and raises the price target from $300 to $325.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 5:03 pm

TRU

TransUnion (NYSE:TRU) has received mixed analyst ratings, with a recent increase in average price targets. Analysts have raised their price targets, indicating a positive outlook. TransUnion's financials show strong revenue growth and net margin, but challenges in ROE, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 5:02 pm

MOH

In the past three months, 14 analysts have rated Molina Healthcare (NYSE:MOH), with a mix of bullish and bearish views. The average 12-month price target is $371.36, a 3.2% decrease from the previous target. Molina Healthcare has shown positive revenue growth but faces challenges with net margins. Analysts' ratings and price targets provide insights into the company's market standing.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 5:01 pm

BAX

Six analysts have shared their evaluations of Baxter Intl (NYSE:BAX) over the last three months, with most ratings being indifferent. The average 12-month price target has decreased by 4.17% to $38.17. Analysts have adjusted their ratings and price targets, reflecting mixed sentiments. Baxter's financial metrics show challenges, including a negative net margin and high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 5:01 pm